Budczies, Jan 1970-
Jan Budczies German researcher
VIAF ID: 67390263 (Personal)
Permalink: http://viaf.org/viaf/67390263
Preferred Forms
- 100 1 _ ‡a Budczies, Jan ‡d 1970-
- 100 1 _ ‡a Budczies, Jan ‡d 1970-
- 100 0 _ ‡a Jan Budczies ‡c German researcher
4xx's: Alternate Name Forms (5)
5xx's: Related Names (5)
- 551 _ _ ‡a Berlin ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _ ‡a Berlin ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 551 _ _ ‡a Heidelberg ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Institut für Pathologie ‡g Berlin ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universität Heidelberg ‡b Pathologisches Institut ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types | |
color-flavor transformation and its applications to quantum chromodynamics | |
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases | |
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization | |
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma | |
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | |
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma | |
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary | |
Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data. | |
LINC00152 Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma | |
Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer | |
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients | |
Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer | |
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients | |
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis | |
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. | |
Variant classification in precision oncology |